Research context (RUO): this page compares two GHRH analogues on the basis of published laboratory and clinical research. The information is intended solely for in vitro research and does not constitute medical advice or instructions for use.
Sermorelin vs Tesamorelin: the difference explained
The comparison sermorelin vs tesamorelin comes up often in research on the growth hormone axis, because both peptides target the same receptor yet differ completely in stability. Sermorelin is the classic, short GHRH fragment; tesamorelin is a chemically stabilised variant that stays intact far longer. That single structural difference determines almost everything: the half-life, the dosing interval in research protocols and the extent to which an effect is measurable in tissue.
What both peptides have in common
Sermorelin and tesamorelin are both analogues of growth hormone-releasing hormone (GHRH), the hypothalamic signal that prompts the pituitary to release growth hormone. They bind to the same GHRH receptor and therefore act through the natural pulsatile route, rather than by adding growth hormone itself. In research models this means that the negative feedback via somatostatin and IGF-1 remains intact — an important difference from exogenous growth hormone.
Sermorelin: the minimal active fragment
Sermorelin consists of the first 29 amino acids of human GHRH (GHRH 1-29). That is the shortest stretch that still fully activates the receptor; the remaining 15 amino acids of the natural hormone are not required for receptor binding. The drawback of that minimal structure is enzymatic vulnerability: the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the peptide at the N-terminus, so the plasma half-life is only a few minutes. In experimental set-ups this produces a short, sharp pulse that closely mirrors the physiological release pattern.
Tesamorelin: a trans-3-hexenoyl group as protection
Tesamorelin has the same GHRH 1-29 backbone, but with a trans-3-hexenoyl group attached to the N-terminal tyrosine. That fatty acid tail blocks precisely the site where DPP-4 would cleave and also increases binding to plasma proteins. The result is a considerably longer circulation time and a higher exposure per administration. Tesamorelin is the only GHRH analogue to have reached an approved indication in clinical research, which means that a relatively large body of published pharmacokinetic data is available.
The two analogues side by side
| Feature | Sermorelin | Tesamorelin |
|---|---|---|
| Structure | GHRH 1-29, unmodified | GHRH 1-29 with trans-3-hexenoyl group |
| Number of amino acids | 29 | 29 plus fatty acid modification |
| Receptor | GHRH receptor | GHRH receptor |
| Sensitive to DPP-4 | Yes, strongly | No, N-terminus is shielded |
| Plasma half-life | A few minutes | Roughly half an hour to an hour |
| Release pattern in research | Short, physiological pulse | Longer, flatter exposure |
| Volume of clinical literature | Limited, mostly older | Extensive, including phase 3 |
| Typical research objective | Pituitary function diagnostics | Visceral adipose tissue, IGF-1 response |
Why DPP-4 makes all the difference
Virtually every difference in the table above traces back to a single enzyme. DPP-4 removes dipeptides from the N-terminus of peptides with a specific pattern, and GHRH 1-29 fits that pattern exactly. Research into GHRH analogues therefore largely revolves around the question of how to shield that cleavage site without losing receptor binding. Tesamorelin solves this with a fatty acid group; other lines of research use amino acid substitutions at position 2. Comparing both peptides in the same experiment effectively measures the effect of enzymatic stability on receptor signalling.
Pulsatile versus continuous: two research models
The growth hormone axis responds not only to the amount of signal, but also to the pattern. A short pulse activates the pituitary and then leaves room for somatostatin to damp the system down again; that is the model sermorelin fits. Longer exposure, as with tesamorelin, shifts the profile towards a higher average IGF-1 level. In comparative research these are therefore not two doses of the same compound, but two fundamentally different stimulation patterns. Anyone designing a protocol would do well to align the measurement time point accordingly: with sermorelin the peak falls within half an hour, with tesamorelin much later and broader.
How they relate to the GHRP peptides
Sermorelin and tesamorelin act via the GHRH receptor, whereas peptides such as ipamorelin, GHRP-2 and GHRP-6 act via the ghrelin receptor. Those two routes are synergistic in research models: combined, they produce a stronger response than the sum of the two separately, because GHRP peptides also suppress somatostatin. For a broader comparison within that class, Ipamorelin vs CJC-1295 vs sermorelin is the starting point, and for the ghrelin side GHRP-2 vs GHRP-6 vs hexarelin.
Where CJC-1295 sits in this spectrum
CJC-1295 is a third solution to the same stability problem. In the variant without DAC it comes down to amino acid substitutions that slow DPP-4 degradation; with DAC the peptide is additionally coupled covalently to albumin, which extends the half-life to days. This creates a spectrum from short to long: sermorelin, then CJC-1295 without DAC, then tesamorelin, then CJC-1295 with DAC. That difference is worked out in CJC-1295 with DAC vs without DAC.
Handling and reconstitution in the laboratory
Both peptides are supplied lyophilised and are stable in that form for long periods at two to eight degrees Celsius. After reconstitution with bacteriostatic water the shelf life is limited and storage must be cold and dark. Because of the fatty acid group, tesamorelin is slightly more hydrophobic than sermorelin; dissolve it gently down the wall of the vial and avoid shaking, since foaming promotes aggregation. Calculate the required volumes with our reconstitution calculator.
Quality & purity
In a comparative experiment between two analogues, batch quality is decisive: a purity difference of a few percent can overshadow the measured difference between the peptides. Every batch we supply comes with a certificate of analysis showing HPLC purity and mass spectrometry, and is independently verified by an external laboratory. How seriously we take that verification is clear here: why we rejected a batch.
Frequently asked questions about sermorelin and tesamorelin
Are sermorelin and tesamorelin the same peptide?
No, but they do share the same 29-amino-acid backbone. Tesamorelin additionally carries a trans-3-hexenoyl group at the N-terminus, which counters enzymatic degradation.
Which of the two has the longer half-life?
Tesamorelin, by a wide margin. Sermorelin is broken down within a few minutes, whereas tesamorelin stays in circulation considerably longer because the DPP-4 cleavage site is shielded.
Do both peptides act on the same receptor?
Yes. Both are GHRH analogues and bind to the GHRH receptor on the pituitary. The difference lies in stability and duration of exposure, not in the point of action.
Why is there more clinical research on tesamorelin?
Tesamorelin was developed as a medicine and therefore went through phase 3 research, including into visceral adipose tissue. Sermorelin was used mainly in diagnostic research on pituitary function.
Can they be compared in the same experiment?
They can, but the measurement protocol has to be adjusted: the peak response occurs much earlier with sermorelin than with tesamorelin. Otherwise a single measurement time point gives a distorted picture.
Read more & research at Peplife
- Buy Sermorelin (RUO)
- Buy Tesamorelin (RUO)
- All GH axis peptides
- Sermorelin research
- Tesamorelin research
- Ipamorelin vs CJC-1295 vs sermorelin
- CJC-1295 with DAC vs without DAC
- GHRP-2 vs GHRP-6 vs hexarelin
- Ipamorelin research
Sources: PubChem — Sermorelin · PubChem — Tesamorelin · GHRH analogues and pituitary function, PMC · Tesamorelin phase 3 research, NEJM · Tesamorelin, effect on visceral adipose tissue, PubMed · GHRH 1-29 pharmacology, PMC
Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.
Do you want to characterise both GHRH analogues under identical conditions? Sermorelin and tesamorelin are available from us with a batch-specific certificate of analysis and independent verification.